Pharnext Appoints Amit Kohli as Chief Operating Officer
April 26 2018 - 12:00PM
Business Wire
Regulatory News:
Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA),
a biopharmaceutical company pioneering a new approach to the
development of innovative drug combinations based on big genomic
data and artificial intelligence, today announced the appointment
of Amit Kohli, a senior healthcare industry executive, as Chief
Operating Officer (COO). Mr. Kohli is responsible for leading
Pharnext’s corporate strategy and operations.
“Amit is a seasoned leader with over 20 years’ experience in the
healthcare industry, and we are thrilled he is joining Pharnext,”
said Prof. Daniel Cohen, M.D., Ph.D., Co-Founder and Chief
Executive Officer of Pharnext. “We are deeply impressed with
Amit’s results-oriented track record, and his ability to drive
business strategy and operations across the pharma, medtech and
clinical diagnostics sectors. We believe Pharnext will greatly
benefit from his extensive cross-functional leadership experience
especially as our first-in-class orphan drug, PXT3003, for the
treatment of Charcot-Marie-Tooth disease type 1A, is set to release
Phase 3 trial data before the end of 2018.”
Before joining Pharnext, Mr. Kohli was a General Manager of
clinical diagnostics at Eurofins in Brussels, where he lead
business expansion across Europe and the Middle East. Prior to
that, he was a Regional Business Director at Becton Dickinson,
focused on delivering business growth in Russia, Turkey, the Middle
East and Africa. Mr. Kohli also held a number of leadership roles
at Sanofi in sales, marketing, finance, supply chain and
manufacturing. During his decade and a half with Sanofi, Mr. Kohli
lived and worked in Mumbai, Frankfurt, London, Helsinki and
Paris.
Mr. Kohli earned an M.B.A. from the Management Development
Institute (MDI) Gurgaon, in India, and a Bachelor of Engineering
from the University of Pune in India.
About PharnextPharnext is an advanced clinical-stage
biopharmaceutical company developing novel therapeutics for orphan
and common neurodegenerative diseases that currently lack curative
and/or disease-modifying treatments. Pharnext has two lead products
in clinical development. PXT3003 is currently in an international
Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type
1A and benefits from orphan drug status in Europe and the United
States. The results of this trial are expected in the second half
of 2018. PXT864 has generated positive Phase 2 results in
Alzheimer’s disease. Pharnext has developed a new drug discovery
paradigm based on big genomic data and artificial intelligence:
PLEOTHERAPY™. The Company identifies and develops synergic
combinations of drugs called PLEODRUG™ offering several key
advantages: efficacy, safety and robust intellectual property. The
Company was founded by renowned scientists and entrepreneurs
including Professor Daniel Cohen, a pioneer in modern genomics and
is supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris
(ISIN code: FR0011191287).For more information, visit
www.pharnext.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180426006223/en/
PharnextXavier PaoliChief Commercial
Officerinvestors@pharnext.com+33 (0)1 41 09 22 30orInvestor
Relations (Europe)MC Services AGAnne
Henneckeanne.hennecke@mc-services.eu+49 211 529252 22orInvestor
Relations (U.S.)Stern Investor Relations, Inc.Matthew
Shinsekimatthew@sternir.com+1 212 362 1200orFinancial
Communication (France)ActifinStéphane Ruizsruiz@actifin.fr+33
(0)1 56 88 11 15orMedia Relations (Europe)ALIZE RPAurore
GangloffCaroline Carmagnolpharnext@alizerp.com+33 (0)1 44 54 36
66orMedia Relations (U.S.)RooneyPartnersKate
Barrettekbarrette@rooneyco.com+1 212 223 0561
Pharnext (EU:ALPHA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pharnext (EU:ALPHA)
Historical Stock Chart
From Sep 2023 to Sep 2024